Literature DB >> 28836132

Lactate Levels with Chronic Metformin Use: A Narrative Review.

Weiyi Huang1, Ronald L Castelino2,3, Gregory M Peterson4,5.   

Abstract

Metformin has been associated with lactic acidosis. Lactate levels are not commonly tested in clinical practice, and it is unclear to what extent metformin would typically increase lactate levels with chronic use. The aim of this review was to determine whether regular monitoring of the plasma lactate level would be beneficial in avoiding lactate accumulation and, ultimately, minimising the incidence of lactic acidosis in metformin-treated patients.A comprehensive search of PubMed, Embase, Web of Science, Cochrane and International Pharmaceutical Abstracts databases covering the period up to 30 May 2017 was performed. Search terms included combinations of terms and keywords, including "metformin", "lactate", "lactic acid" and "lactic acidosis". Cases series of lactic acidosis or metformin-associated lactic acidosis were excluded.Of 1539 potentially relevant articles, a total of 52 reported lactate levels from routine/regular pathological tests in metformin users. The studies were subdivided into four themes, regarding metformin usage and the reported lactate levels in patients who: (1) did not have contraindications to the use of metformin; (2) had contraindications, or renal impairment but without other contraindications; (3) exercised; or (4) also received any nucleoside reverse transcriptase inhibitor. Studies have reported that metformin treatment could increase lactate level of users. However, most results showed that the lactate level remained in the normal range.No definitive conclusions on the benefits of regular lactate monitoring in patients taking metformin can be made. Future research on larger populations focusing on the measurement of lactate levels with continuous metformin use is warranted.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28836132     DOI: 10.1007/s40261-017-0564-6

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  86 in total

1.  The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database.

Authors:  F Kajbaf; J-D Lalau
Journal:  Diabet Med       Date:  2013-03       Impact factor: 4.359

Review 2.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

3.  Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial.

Authors:  P Brunetti; G Pagano; C Turco; M Gori; G Perriello
Journal:  Diabetes Nutr Metab       Date:  2004-12

4.  The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis.

Authors:  Janna K Duong; Timothy J Furlong; Darren M Roberts; Garry G Graham; Jerry R Greenfield; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

5.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

6.  Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy.

Authors:  Amy T Calabrese; Kim C Coley; Stacey V DaPos; Dennis Swanson; R Harsha Rao
Journal:  Arch Intern Med       Date:  2002-02-25

7.  Lactate kinetics and individual anaerobic threshold.

Authors:  H Stegmann; W Kindermann; A Schnabel
Journal:  Int J Sports Med       Date:  1981-08       Impact factor: 3.118

8.  One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.

Authors:  I W Campbell; D G Menzies; J Chalmers; A M McBain; I R Brown
Journal:  Diabete Metab       Date:  1994 Jul-Aug

9.  Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study.

Authors:  Morgana L Mongraw-Chaffin; Kunihiro Matsushita; Frederick L Brancati; Brad C Astor; Josef Coresh; Stephen O Crawford; Maria Inês Schmidt; Ron C Hoogeveen; Christie M Ballantyne; Jeffery Hunter Young
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

10.  Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

Authors:  Michael Bodmer; Christian Meier; Stephan Krähenbühl; Susan S Jick; Christoph R Meier
Journal:  Diabetes Care       Date:  2008-09-09       Impact factor: 17.152

View more
  8 in total

1.  Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes.

Authors:  Inês H Vieira; Luísa M Barros; Carla F Baptista; Dírcea M Rodrigues; Isabel M Paiva
Journal:  Clin Diabetes       Date:  2022-01

Review 2.  Metformin and cardiorenal outcomes in diabetes: A reappraisal.

Authors:  John R Petrie; Peter R Rossing; Ian W Campbell
Journal:  Diabetes Obes Metab       Date:  2020-02-18       Impact factor: 6.577

Review 3.  A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan.

Authors:  Ibrahim Mohammed; Morley D Hollenberg; Hong Ding; Chris R Triggle
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-05       Impact factor: 5.555

Review 4.  The Function of Metformin in Aging-Related Musculoskeletal Disorders.

Authors:  Yanhong Song; Ziyi Wu; Ping Zhao
Journal:  Front Pharmacol       Date:  2022-03-08       Impact factor: 5.810

5.  AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures.

Authors:  Kathryn A Salvati; Matthew L Ritger; Pasha A Davoudian; Finnegan O'Dell; Daniel R Wyskiel; George M P R Souza; Adam C Lu; Edward Perez-Reyes; Joshua C Drake; Zhen Yan; Mark P Beenhakker
Journal:  Brain       Date:  2022-07-29       Impact factor: 15.255

Review 6.  Metformin: When Should We Fear Lactic Acidosis?

Authors:  Stefania Di Mauro; Agnese Filippello; Alessandra Scamporrino; Francesco Purrello; Salvatore Piro; Roberta Malaguarnera
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

7.  Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach.

Authors:  Lina A Dahabiyeh; Muhammad Mujammami; Reem H AlMalki; Tawfiq Arafat; Hicham Benabdelkamel; Assim A Alfadda; Anas M Abdel Rahman
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

Review 8.  Targeting Myotonic Dystrophy Type 1 with Metformin.

Authors:  Mikel García-Puga; Ander Saenz-Antoñanzas; Ander Matheu; Adolfo López de Munain
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.